CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer-Reference-Cited by-同舟云学术

CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer

Published:2024-01-08 Issue:14 Volume:20 Page:891-901
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncol.

Author:

Steinberg Gary D¹^ORCID,Shore Neal D²,Redorta Joan Palou³,Galsky Matthew D⁴,Bedke Jens⁵,Ku Ja Hyeon⁶,Kretkowski Michal⁷,Hu Hailong⁸,Penkov Konstantin⁹,Vermette Jennifer J¹⁰,Tarazi Jamal C¹¹,Randall Alison E¹²,Pierce Kristen J¹³,Saltzstein Daniel¹⁴,Powles Thomas B¹⁵

Affiliation:

1. Department of Urology, Rush University Medical Center, Chicago, IL, USA

2. Carolina Urologic Research Center, Grand Strand Urology, 823 82nd Parkway, Myrtle Beach, SC29572, USA

3. Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, C. de Cartagena 340-350, 08025Barcelona, Spain

4. The Tisch Cancer Institute, Mount Sinai, 1190 One Gustave L. Levy Place, New York, NY10029, USA

5. Department of Urology, Eberhard Karls University Tübingen, Geschwister-Scholl-Platz, 72074Tübingen, Germany

6. Department of Urology, Seoul National University Hospital, 101 Daehak-ro Jongno-gu, Seoul03080, Republic of Korea

7. Clinical Research Center, Spolka z Ograniczona, Feliksa Nowowiejskiego 5, 61-731Poznań, Poland

8. Institute of Urology, Second Hospital of Tianjin Medical University, 23 Pingjiang Road, Hexi District, Tianjin300211, China

9. Private Medical Institution Euromedservice, Suvorovskiy Prospekt, 60, St Petersburg, Russia

10. Pfizer Oncology, Pfizer, 1 Portland Street, Cambridge, MA02139, USA

11. Pfizer Oncology, Pfizer, 10646 Science Center Drive, San Diego, CA92121, USA

12. Pfizer Oncology, Pfizer, 235 East 42nd Street, New York, NY10017, USA

13. Pfizer Oncology, Pfizer, 280 Shennecossett Road, Groton, CT06340, USA

14. Division of Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX78229, USA

15. Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 5PZ, UK

Funder

Pfizer

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.2217/fon-2023-0271

Reference36 articles.

1. International Agency for Research on Cancer (IARC). Bladder (2020). Available at: https://gco.iarc.fr/today/data/factsheets/cancers/30-Bladder-fact-sheet.pdf (Accessed: 10January2023).

2. Epidemiology of bladder cancer;Saginala K;Med. Sci. (Basel),2020

3. Review on gender differences in non-muscle invasive bladder cancer

4. Female Gender and Carcinoma In Situ in the Prostatic Urethra Are Prognostic Factors for Recurrence, Progression, and Disease-Specific Mortality in T1G3 Bladder Cancer Patients Treated With Bacillus Calmette-Guérin

5. Intravesical gemcitabine for non-muscle invasive bladder cancer;Han MA;Cochrane Database Syst. Rev.,2021

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non–muscle-invasive Bladder Cancer;European Urology Oncology;2024-06

2. Treatment Modalities for Non-Muscle Invasive Bladder Cancer: An Updated Review;Cancers;2024-05-11

3. Pharmacokinetics, safety, and efficacy of an alternative dosing regimen of sasanlimab in participants with advanced NSCLC and other malignancies;Therapeutic Advances in Medical Oncology;2024-01